Optometry on front line to identify early signs of Alzheimer’s, Parkinson’s
The good news is that a tremendous amount of
research points to several ocular biomarkers for
neurodegenerative disease — and puts optometry center stage in addressing these public health crises in the future.
FDA accepts Biogen’s aducanumab biologics license application for alzheimer's disease with priority review
Biogen announced that the FDA has
accepted the Biologics License Application
for aducanumab, an investigational treatment for Alzheimer’s disease.
Necessity Is the Mother of Collaborative Care between Optometrists and Ophthalmologists
Collaborative care models-optometrists and
ophthalmologists working together on patient care-are emerging as a way to reduce some of the strain caused by growing patient volume.
Novartis gives up on Xiidra's EU approval, endangering payoff from $3.4B Takeda buyout
Novartis has withdrawn an application for Xiidra
a former Shire dry eye med it just paid $3.4 billion up front to get from Takeda.
US FDA approves updated Novartis Beovu® label, to include additional safety information
Novartis worked with US FDA to update
Beovu (brolucizumab) prescribing information
to guide healthcare professionals in their treatment of wet AMD patients
Optometrists are helping assure advocates can make a stand and positively affect the future of optometric care
Doctors of optometry there are turning up
the heat in response to a November ballot
measure that would overturn a recent scope of practice law enacted by the state legislature last year.